NanoViricides, Inc., a clinical-stage developer of broad-spectrum antiviral drugs, will present today at the Spartan Capital Investor Conference in New York City. The company's presentation will focus on its novel nanoviricide technology platform and pipeline of antiviral drug candidates designed to prevent viral escape. This approach represents a significant departure from traditional antiviral development strategies that often face challenges with viral resistance and mutation.
The company's lead drug candidate, NV-387, embodies a broad-spectrum antiviral approach planned for development against multiple respiratory viral infections including RSV, COVID-19, Long COVID, influenza, and MPOX/Smallpox infections. Another advanced candidate, NV-HHV-1, targets the treatment of Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials, though specific timelines for Investigational New Drug applications remain dependent on external collaborators and consultants. This development stage marks a critical milestone in translating laboratory research into potential clinical applications.
NanoViricides' technology foundation stems from its relationship with TheraCour Pharma, Inc., from which the company has obtained broad, exclusive, sub-licensable field licenses for drugs developed in several licensed fields. The company's business model, established at its foundation in 2005, involves licensing technology from TheraCour for specific application verticals targeting specific viruses. This strategic approach allows the company to leverage established technological platforms while focusing resources on specific therapeutic areas.
The company's platform technology and programs are based on the TheraCour nanomedicine technology, which NanoViricides holds under worldwide exclusive perpetual licenses for treating numerous viral diseases. These include Human Immunodeficiency Virus, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Asian Bird Flu, Dengue viruses, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. Additional information about the company's technology and pipeline is available at https://www.nanoviricides.com.
Beyond its current pipeline, NanoViricides is developing drugs against multiple other viral diseases including oral and genital Herpes, viral eye diseases such as EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The company has indicated intentions to obtain licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful. This expansive development strategy positions the company to address multiple unmet medical needs across diverse viral pathogens.
As with all pharmaceutical development, the company acknowledges the inherent risks in drug development, noting that the path requires substantial capital and lengthy timelines. There can be no assurance that any of the company's pharmaceutical candidates will demonstrate sufficient effectiveness and safety for human clinical development or that successful laboratory results will translate to successful clinical trials or commercial products. Investors seeking additional information can access the company's newsroom at https://ibn.fm/NNVC. The company's presentation at the investor conference represents an important opportunity to communicate its progress and strategy to the investment community during a critical phase of development.
